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1. Case presentation
This case presents a 64-yr-old, healthy man who noted
microscopic haematuria and immediately sought an
appointment with the physician. He was a long-term heavy
smoker, which alerts the physician to bladder cancer. The
standard practice in Austria includes an ultrasound scan,
which revealed a small lesion in the bladder of this patient.
Cytology is suspicious for high-grade cancer, and trans-
urethral resection of the bladder (TURB) reveals a single
primary unifocal 2.0-cm tumour on the left side.
During TURB with blue light using hexaminolevulinate
(Hexvix), there were two foci of concomitant carcinoma in
situ (CIS). The pathology revealed PT1 high grade without
lymphovascular invasion or variant histology, with two foci
of CIS, that is, a pure urothelial T1 2.0-cm unifocal non–
muscle-invasive bladder cancer (NMIBC) lesion.
At this point, the physician opted for a repeat TURB (re-
TURB). This revealed no residual tumour, and the computed
tomography (CT) urogram was normal as well. The question
is: What is the best treatment for this patient?
2. Option A: the case for conservative therapy
Why should we choose conservative intravesical treatment
in this patient—a healthy 64-yr-old man with T1 grade 3
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Abstract
A relatively young (64-yr old) long-term heavy smoker but otherwise very healthy
man is diagnosed with a primary unifocal left-side tumour (urothelial, T1 high
grade), but no lymphovascular invasion and no variant histology. We discuss
whether treatment with intravesical bacillus Calmette-Guérin vaccine will be
sufﬁcient or early radical cystectomy is at least equally preferred regarding patient
beneﬁt, safety, and quality of life.
Patient summary: A patient with a single high-grade T1 bladder tumour without
aggressive features (eg, lymphovascular invasion or variant tumour aspects) will be
adequately treated with bacillus Calmette-Guérin intravesical therapy delivered
into the bladder, followed by 3 yr of maintenance. However, all decisions should be
taken with the patient in a shared decision-making process, including a discussion
regarding removal of the bladder.
© 2019 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).
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(T1G3) NMIBC, no residual tumour after re-TURB, and a
negative CT urogram?
2.1. Evidence
2.1.1. BCG is effective in T1G3
Intravesical immunotherapy with bacillus Calmette-Guérin
(BCG) is generally effective for T1G3 disease. A large
retrospective study of 2530 T1G3 patients [1] treated with
BCG and followed up for an average of 5.2 yr found that 79%
of patients did not experience disease progression; only 23%
received radical cystectomy, meaning that >70% kept their
bladder beyond 10 yr and the cancer-specific death rate was
as low as 9%.
2.1.2. There is no proof that cystectomy is superior to BCG in T1G3
No prospective study has compared BCG with cystectomy in
T1G3 NMIBC. Retrospective comparative series have pointed
out a potential advantage of radical cystectomy only in T1G3
associated with negative prognostic factors such as CIS
[2]. However, radical cystectomy is far from guaranteeing cure
in T1G3. In the milestone cystectomy series from Stein et al
[3], patients who received a radical cystectomy for a true
T1G3 (ie, T1 disease in the radical cystectomy specimen) had a
20% risk of recurrence at 10 yr. Since bladder cancer recurring
after radical cystectomy is usually only amenable to palliative
treatment, it is reasonable to assume that no more than 80%
of T1G3 patients will survive despite early radical cystectomy,
figures that almost overlap the 10-yr cancer-specific survival
of 85% found in a large BCG series [1].
2.1.3. No residual tumour at re-TURB carries a good prognosis
According to the current guidelines [4], patients with any T1
disease should undergo a mandatory re-TURB. Does the
absence of residual disease at re-TURB translate into a better
disease outcome? In 710 NMIBC patients with T1G3 disease
[5], the risk of progression to muscle-invasive bladder
cancer differed widely, depending on the pathologic results
of a re-TURB. Patients who were found to be T0 at re-TURB
had the lowest risk of progression at 5 yr (9%).
Similar variability in outcomes of T1G3 according to re-
TURB findings was observed in a more recent and larger
study of T1G3 in patients who subsequently received BCG
[6]. Out of a total of 951 patients undergoing a re-TURB,
267 patients without a residual tumour had the lowest risk
of progression: 14% at 10 yr, with cancer-specific survival of
94% (cancer-specific death rate 6%).
A retrospective analysis assessed the outcomes of radical
cystectomy for T0 in the surgical specimen [7]. Results were
reported for a subgroup of 68 patients with T1 disease with
no residual tumour in the radical cystectomy specimen,
showing a 16% recurrence rate and a 5.2% death rate at 10 yr.
This observation indicates that the prognosis for T1G3
patients receiving early radical cystectomy without evi-
dence of disease in the surgical specimen overlaps that of
conservatively treated T1G3 patients found to be T0 in the
re-TURB results. Even for its best scenario, radical cystec-
tomy does not seem to confer any advantage over
conservative therapy.
2.1.4. T1G3 with no negative prognostic factors is a good indication
for conservative therapy
A number of prognostic factors, alone or in combination
with T1G3, are notoriously deemed to negatively affect the
risk of progression [8].
As shown in Table 1, when T1G3 is associated with one or
more negative prognostic factors, the risk of progression
becomes significant to the point that early radical cystec-
tomy is strongly advocated. Of note, the current clinical case
of a T1G3 with a limited quantity of concomitant CIS that
was found to have no residual tumour on re-TURB has none
of the mentioned negative prognostic factors, thus repre-
senting the ideal candidate for conservative therapy.
2.2. Conclusion and treatment recommendation
Based on the current evidence, solitary T1G3 disease with
no residual tumour at re-TURB should ideally be treated
conservatively with intravesical BCG. This patient carries a
relatively low risk of progression, especially because there
are no other bad prognostic features. There is no proof that
early radical cystectomy, even in the best scenario of a
pathologic T0, would have a better prognosis. Radical
cystectomy does not guarantee cure of a T1G3 tumour;
rather it conveys a risk of cancer-specific death as high as
20%. Hence, patients such as the one discussed here can be
spared aggressive treatment and given the chance to
maintain their native bladder in up to 75% of cases at no
additional risk of death.
3. Option B: the case for radical cystectomy
3.1. Evidence
3.1.1. Quality control of the case: possibility of pathologic variants
When considering patients such as the one discussed in this
paper, the first step is to re-review the pathology and
radiology. We have multidisciplinary treatment (MDT)
meetings are conducted in the UK, where such reviews
are performed. Patients with high-grade or muscle-invasive
bladder cancer are cared for in cancer centres following
MDT review and National Institute for Health and Care
Excellence (NICE) guidance [9]. A review of imaging and
Table 1 – Single or combinations of prognostic factors predicting a
“very high” risk of progression in T1G3 disease.
Prognostic factor Risk of
progression
Persistent T1 disease at re-TURB 25–75%
T1G3 with CIS + tumour size
>3 cm + age >70 years
60%
T1G3 + female gender + CIS
prostatic urethra
40%
T1 with depth of invasion
>3 mm and diameter of
invasive focus >6 mm
100%
Variant histology (micropapillary) 24%
Lymphovascular invasion 34%
CIS = carcinoma in situ; Re-TUR = repeat transurethral resection.
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pathology is performed by specialised uroradiologists and
uropathologists, who may identify differences with the
initial report and pathologic variants of urothelial cell
carcinoma. In a recent series of 589 TURB cases [10], variant
histology was missed in 44% of the referrals coming into the
MDT review process. These variant cancers are usually more
aggressive, and so it is important to identify this.
3.1.2. Risk-benefit of BCG
Assuming that the diagnosis of high-risk NMIBC without the
presence of pathologic variants is correct, in cases such as
the present one, Dr. Catto’s centre offers three options:
intravesical BCG, radical cystectomy, or a clinical trial (eg,
BRAVO [11] or IROC [12]). Dr. Gontero has provided an
excellent summary of the general advantages of intravesical
BCG in the previous section of this article. However, Dr.
Catto’s personal opinion is that the support in favour of BCG
appears more robust than the evidence suggests (although
it can be admitted that many uro-oncologists may not share
this concern).
For example, much of the evidence for the benefit of BCG
comes from Sylvester et al’s [13] first meta-analysis in 2002
(updated with new data in 2005 [14]). This showed a 27%
relative reduction of disease progression with BCG (in the
same population as the present patient case). This created
the view that BCG is associated with a real reduction in
progression (and recurrence) of disease. In other words,
(1) the overall progression rates seen with BCG are low and
many patients keep their bladders; (2) keeping the bladder
is beneficial because it is presumed that one has better
quality of life (QOL) than after radical cystectomy; (3) the
Sylvester meta-analysis seemed to suggest that BCG is less
toxic than radical cystectomy; and (4) if BCG fails, a salvage
radical cystectomy is possible with no drawbacks. All these
apparent benefits support the concept that delaying a
radical cystectomy has no, or very little, harm.
However, each of these assumptions may not be proved
or necessarily true as outlined below.
3.1.3. Critique of BCG meta-analyses: progression versus recurrence
Disease progression and mortality from T1G3 high-risk
NMIBC are clearly correlated with time after initiation of
therapy (eg, the data from Kulkarni et al [15] as plotted in
Fig. 1), illustrating that both variables are associated with
time [8].
The first concern regarding the Sylvester meta-analyses
is that the median follow-up was only 2.5 yr. Since many of
the events would not have occurred in that population at
that stage, this duration for the assessment of disease
progression and mortality is premature for supporting the
analysis’ conclusion regarding the efficacy of BCG therapy.
There is also concern about the disease cohorts in the
Sylvester meta-analysis. Whilst most clinicians use BCG for
high-grade NMIBC (as for this patient), most patients in
Fig. 1 – Correlation of disease progression and mortality with duration of follow-up. MA = meta-analysis. Adapted from Kulkarni et al [15].
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these meta-analyses were of intermediate risk. According to
the European Organisation for Research and Treatment of
Cancer tables [14], the risk of progression is 5% for grade 1,
10–15% for grade 2, and 25–75% for grade 3 NMIBC. In the
meta-analyses Sylvester et al [13, Table 2], only 7.6% of the
tumours treated with BCG were high-grade disease, and as a
result, these percentages for high-grade data do not apply
for the population in the present case.
A more recent meta-analysis of the data of 2820 patients
[16] found no statistically significant benefit of BCG over other
treatments regarding the risk of progression, and certainly not
the 27% relative protection against progression reported for
BCG in the Sylvester meta-analyses. Across the entire
population of the individual patient meta-analysis by Mal-
mstrom et al [16], there was very little difference in mortality.
Therefore, in total, we have to question whether BCG is as
effective as we thought.
3.1.4. QOL with BCG
A further key unresolved question is the supposed benefit of
intravesical BCG therapy versus that of radical cystectomy
on QOL. In his personal experience as a busy urologist, a
member of patient focus and social media groups, and an
advisor to one of the UK charities, Dr. Catto hears that many
patients worry about BCG (ie, how is their cancer
responding) and finds that it has many side effects.
Although the patients may not communicate these to their
physicians, they have anxiety and concern about their
urinary symptoms, the number 1 among them being
anxiety about side effects of BCG in particular (including
cystitis and bladder pain), as well as concern about whether
there is a bladder tumour and whether they should worry
about these things. All these things are extremely bother-
some for patients, and if we look at the very few prospective
data, they are not reporting fantastic QOL on BCG that is
allowing them to preserve their bladder.
Even though published results in well-controlled trials
show a good compliance rate with BCG [8,16,17], in practice,
only about one-third of the patients complete 3 yr with
BCG; approximately half of the patients do not complete the
3-yr stop because of perceived lack of efficacy [18,19], and
the other half stop BCG due to toxicity [8,17,20]. Many
patients complete only about 1 yr of BCG because of issues
with tolerability and practicality of BCG [8,16–18].
3.1.5. QOL and recovery after radical cystectomy
Although based on little evidence, most physicians know
that within 6 mo after cystectomy most patients find that
their QOL is back to where it was before the discovery of
their high-grade bladder cancer, if not better. From a small
study (81 patients) interviewed preoperatively [21], most
reported a return to preoperative QOL at 1 yr after
cystectomy. Overall, nine out of 10 patients in the UK
reported the same or better QOL at 6 mo after cystectomy
versus only one in 10 who had complications; although this
is <100%, it appears that after cystectomy a patient’s QOL
approaches the normal value reasonably quickly.
In addition, the modern cystectomy procedure is no
longer the morbid option that it used to be. The mortality
rate is low, and current enhanced recovery after surgery
rates mean that patients are being discharged to go home
much faster and they are much better [12].
3.1.6. Is delay of radical cystectomy detrimental?
One of the arguments in favour of intravesical therapy with
BCG is the assumption that salvage radical cystectomy (for
BCG failures) can be performed without any detrimental
impact on cancer survival rates. Various series looking at
this comparison have been published [2,22–25], with some
showing no benefit of delaying radical cystectomy, some
showing benefit of delaying surgery, and some finding harm
to the patient with delay (recently reviewed by Klaassen
et al [8]). It seems logical that if a physician delays definitive
treatment for a period of time (eg, for a trial of BCG) and
finds a progressing invasive tumour, then the patient
outcome will be worse than that if the patient is treated
with immediate definitive radical cystectomy. Given
improvements in radical cystectomy [26], one would
wonder whether the time for primary cystectomy is now.
3.2. Conclusion and treatment recommendation
There appears to be an equipoise between the two
treatments, intravesical BCG and radical cystectomy,
regarding patient benefit, safety, and QOL. For example,
once the number of hospital visits required with BCG is
added, the pros and cons of intravesical therapy versus
radical cystectomy become a lot more equivalent. Further,
remembering that most of these patients are mid-70-yr-old
individuals, the QOL impact of losing the bladder and sexual
function for an average patient is probably similar between
the two treatment strategies. As such, patients should
choose their option, but they should be fully aware of the
risks and benefits of both approaches.
4. Discussion of treatment options
T1HG bladder cancer constitutes approximately 25% of
incident bladder cancers. It has a heterogeneous natural
history, with large variation in reported oncologic out-
comes. Radical cystectomy is considered the best chance
at cure, albeit with a high risk of morbidity, and is
overtreatment for some patients. Treatment with BCG
allows bladder preservation but may risk disease pro-
gression. A number of studies point to the danger in
delaying radical cystectomy in patients with high-risk
disease, and if possible, these patients have the most to
gain from aggressive, early radical therapy. Optimal risk
stratification is essential to individualise patient man-
agement, in order to offer radical cystectomy to those at
the greatest risk of disease progression, while allowing
others to safely pursue bladder-preserving approaches
such as intravesical BCG.
Ideal prognostic factors would identify patients who
may safely be managed with local therapy (ie, TURB plus
intravesical BCG therapy), and differentiate patients who
are at a high risk of progression and would therefore
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benefit most from aggressive treatment (ie, early radical
cystectomy).
For the majority of clinicians, risk stratification of T1
tumours currently relies on standard clinicopathologic
variables such as the presence of concomitant CIS, tumour
multifocality, tumour size >3 cm, deep lamina propria
invasion, and residual T1 after restaging TURB. The
occurrence of more than one (ie, multiple) of these risk
factors at T1HG diagnosis distinguishes candidates who
should be advised to undergo immediate radical cystec-
tomy. These specific high-risk features include any of the
following: younger patients with long life expectancy,
extensive concomitant CIS, multifocal T1HG tumours, and
T1HG disease at re-TURB [27].
Likewise, identification of high-grade disease at the first
cystoscopic follow-up (BCG refractory) and/or T1 or
prostatic urethral disease at any point during follow-up
identifies candidates for early radical cystectomy [4]. Patho-
logic substaging has been proposed as an approach to risk
stratify T1 tumours more accurately. Specifically, T1
tumours have been subclassified as T1a, T1b, or T1c, based
on invasion above, into, or beyond the muscularis mucosa-
vascular plexus. More recently, a meta-analysis highlighted
the prognostic value of pathologic substaging in 15
215 patients from 73 studies, of whom 97.9% had T1
high-grade disease [28]. T1b/c substage, which was
evaluated in 11 studies of 1431 patients, was identified as
the greatest risk factor for progression (hazard ratio [HR]
3.34) and cancer-specific mortality (HR 2.02). Unfortunate-
ly, however, the muscularis mucosa–vascular plexus may
not be evident in up to one-third of cases precluding
pathologic substaging. Accordingly, other pathologic sub-
staging systems have been proposed based on the depth of
invasion measured in millimetres. Indeed, we and others
have supported a substaging system that dichotomised T1
into microinvasive (T1mic, depth 0.5 mm) and extensive
(T1ext, depth >0.5 mm) tumours [29].
In addition to these factors, there are several factors that
are very strong indicators of the need for an early radical
cystectomy: lymphovascular invasion and select variant
histologies. The presence of lymphovascular invasion repre-
sents a particularly important adverse prognostic feature in
NMIBC, as this entity has been associated with significantly
increased risks of progression, metastasis, and mortality
[30,31].
Similarly, any patient with T1HG associated with select
variant urothelial histologies (ie, micropapillary, nested,
plasmacytoid, or sarcomatoid) are at a significantly increased
risk of disease recurrence, progression, and mortality. These
patients are at increased risks of advanced disease and lymph
node metastasis at the time of radical cystectomy. Micro-
papillary bladder cancer is one of the more common variant
histologies with a particular aggressive phenotype for which
BCG is probably less effective. While some authors advocate
proactive immediate radical cystectomy in patients with T1
disease with micropapillary variant component, others argue
that bladder-conserving strategy such as BCG therapy can be
beneficial, with immediate radical cystectomy not being
superior to conservative measures [32].
It is evident that the current risk stratification of T1
based on standard clinicopathologic features remains
imperfect. Younger patients with longer life expectancy;
extensive CIS; variant histology such as nested, micro-
papillary, plasmacytoid, or sarcomatoid; prostatic urethral
involvement; lymphovascular invasion; or residual T1HG
disease at re-TURB [33] should be considered for immediate
radical cystectomy, whilst patients without these features
could reasonably be offered BCG, with early radical
cystectomy reserved for those with recurrent high-grade
disease despite adequate BCG therapy. Obviously, all
decisions must be made with the patient together in a
shared decision-making process based on scientific evi-
dence and personal preferences of the patient and his
family. Conditions for a bladder-preserving strategy include
nononcologic factors such as no/minimal irritative voiding
symptoms, compliance with a strict long-term follow-up,
and readiness to change strategy with early treatment
failure prompting treatment with radical cystectomy.
5. Summary and final treatment recommendation
The current case, a rather young man with a unifocal 2-cm
T1HG tumour, without lymphovascular invasion or variant
histology, but with two small areas of concomitant CIS and
T0 on re-TURB, is certainly a patient with whom the risks,
benefits, and alternatives to immediate radical cystectomy
would be discussed, but for whom a trial of induction
intravesical BCG with the plan for a 3-yr maintenance
therapy would be suggested.
Current strategies for diagnosis, risk stratification, and
treatment are imperfect, but emerging knowledge and
molecular approaches can help us guide our patients with
an optimised individualised evidence-based treatment
strategy. In light of the limitations of standard clinicopath-
ologic features as prognostic variables for patients with T1
disease, it is clear that a need exists for more refined risk
stratification. In this regard, there has been a growing effort
to develop a molecular classification of bladder cancer
[34,35].
New immune strategies and new drug (chemotherapy
and immunotherapy) combinations, in addition to new
biomarkers, will hopefully help urologists further person-
alise therapies for patients with T1 high-grade disease and
ultimately improve outcomes in these difficult to manage,
high-risk patients.
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